Table 1 Patient Demographics and Baseline Characteristics in Studies A and B (Safety Population)
Study A | Study B | |||||||
|---|---|---|---|---|---|---|---|---|
Placebo n = 6 | Navafenterol 300 μg n = 6 | Navafenterol 600 μg n = 6 | Navafenterol 900 μg n = 6 | Placebo n = 6 | Navafenterol 300 μg n = 6 | Navafenterol 600 μg n = 6 | Navafenterol 900 μg n = 6 | |
Age, years | 41.5 (7.6) | 34.0 (5.7) | 44.2 (7.9) | 36.5 (6.8) | 35.7 (6.4) | 30.0 (5.0) | 32.0 (7.8) | 35.5 (8.5) |
Race, n (%) | ||||||||
Asian | 0 | 1 (16.7) | 0 | 0 | 6 (100.0) | 6 (100.0) | 6 (100.0) | 6 (100.0) |
Black/African American | 0 | 0 | 0 | 1 (16.7) | 0 | 0 | 0 | 0 |
White | 6 (100.0) | 5 (83.3) | 6 (100.0) | 5 (83.3) | 0 | 0 | 0 | 0 |
Ethnicity, n (%) | ||||||||
Hispanic or Latino | 1 (16.7) | 0 | 1 (16.7) | 0 | 0 | 0 | 0 | 0 |
Height, cm | 179.7 (4.7) | 179.7 (6.3) | 174.2 (8.0) | 176.8 (3.3) | 168.5 (4.7) | 172.0 (2.6) | 172.8 (5.6) | 170.8 (6.3) |
Weight, kg | 78.0 (11.1) | 85.2 (13.2) | 75.8 (5.25) | 76.2 (8.4) | 64.3 (5.1) | 62.8 (5.3) | 68.0 (9.3) | 64.8 (6.2) |
Body mass index, kg/m2 | 24.1 (2.6) | 26.2 (2.3) | 24.8 (3.7) | 24.3 (1.8) | 22.7 (2.0) | 21.2 (1.3) | 22.7 (2.1) | 22.2 (2.4) |